NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Alemtuzumab

Last Revision: February 28, 2019.

Estimated reading time: 1 minute

CASRN: 216503-57-0

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of alemtuzumab during breastfeeding. Because alemtuzumab is a large protein molecule with a molecular weight of 145,454, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, alemtuzumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant.[1][2][3]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta

References

1.
Bove R, Alwan S, Friedman JM et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124:1157-68. [PubMed: 25415167]
2.
Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19:835-43. [PubMed: 23319073]
3.
Almas S, Vance J, Baker T et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458.9. [PMC free article: PMC4757692] [PubMed: 26966579]

Substance Identification

Substance Name

Alemtuzumab

CAS Registry Number

216503-57-0

Drug Class

  • Breast Feeding
  • Antineoplastic Agents
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

  • Review Basiliximab[Drugs and Lactation Database (...]
    Review Basiliximab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Cetuximab[Drugs and Lactation Database (...]
    Review Cetuximab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Mepolizumab[Drugs and Lactation Database (...]
    Review Mepolizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Rituximab[Drugs and Lactation Database (...]
    Review Rituximab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Golimumab[Drugs and Lactation Database (...]
    Review Golimumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...